Sheets Smith Investment Management’s Viking Therapeutics VKTX Stock Holding History

Sheets Smith Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$351K	Buy	+13,364	New	+$399K	0.23%	94

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sheets Smith Investment Management's VKTX Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in Viking Therapeutics (VKTX) in Q3 2025: 13,364 shares worth $351K. The stake represents 0.23% of the portfolio and ranks #94 among its holdings.

370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Sheets Smith Investment Management held 13,364 shares of Viking Therapeutics worth $351K as of Q3 2025.
Viking Therapeutics was a new Sheets Smith Investment Management position in Q3 2025.
Viking Therapeutics made up 0.23% of Sheets Smith Investment Management's portfolio in Q3 2025, its #94 holding.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.